🎉 M&A multiples are live!
Check it out!

Aquestive Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Aquestive Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Aquestive Therapeutics Overview

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.


Founded

2017

HQ

United States of America
Employees

142

Website

aquestive.com

Financials

LTM Revenue $55.3M

LTM EBITDA -$30.7M

EV

$216M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Aquestive Therapeutics Financials

Aquestive Therapeutics has a last 12-month revenue of $55.3M and a last 12-month EBITDA of -$30.7M.

In the most recent fiscal year, Aquestive Therapeutics achieved revenue of $57.6M and an EBITDA of -$26.6M.

Aquestive Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Aquestive Therapeutics valuation multiples based on analyst estimates

Aquestive Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $50.6M $57.6M XXX XXX XXX
Gross Profit $28.3M $29.8M XXX XXX XXX
Gross Margin 56% 52% XXX XXX XXX
EBITDA $1.2M -$26.6M XXX XXX XXX
EBITDA Margin 2% -46% XXX XXX XXX
Net Profit -$54.4M -$7.9M XXX XXX XXX
Net Margin -108% -14% XXX XXX XXX
Net Debt $24.9M $3.7M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Aquestive Therapeutics Stock Performance

As of April 15, 2025, Aquestive Therapeutics's stock price is $3.

Aquestive Therapeutics has current market cap of $249M, and EV of $216M.

See Aquestive Therapeutics trading valuation data

Aquestive Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$216M $249M XXX XXX XXX XXX $-0.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Aquestive Therapeutics Valuation Multiples

As of April 15, 2025, Aquestive Therapeutics has market cap of $249M and EV of $216M.

Aquestive Therapeutics's trades at 3.9x LTM EV/Revenue multiple, and -7.0x LTM EBITDA.

Analysts estimate Aquestive Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Aquestive Therapeutics and 10K+ public comps

Aquestive Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $216M XXX XXX XXX
EV/Revenue 3.7x XXX XXX XXX
EV/EBITDA -8.1x XXX XXX XXX
P/E -5.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -6.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Aquestive Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Aquestive Therapeutics Valuation Multiples

Aquestive Therapeutics's NTM/LTM revenue growth is 0%

Aquestive Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Aquestive Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Aquestive Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Aquestive Therapeutics and other 10K+ public comps

Aquestive Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 14% XXX XXX XXX XXX
EBITDA Margin -46% XXX XXX XXX XXX
EBITDA Growth -2352% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -46% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 35% XXX XXX XXX XXX
Opex to Revenue 122% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Aquestive Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Aquestive Therapeutics M&A and Investment Activity

Aquestive Therapeutics acquired  XXX companies to date.

Last acquisition by Aquestive Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Aquestive Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Aquestive Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Aquestive Therapeutics

When was Aquestive Therapeutics founded? Aquestive Therapeutics was founded in 2017.
Where is Aquestive Therapeutics headquartered? Aquestive Therapeutics is headquartered in United States of America.
How many employees does Aquestive Therapeutics have? As of today, Aquestive Therapeutics has 142 employees.
Who is the CEO of Aquestive Therapeutics? Aquestive Therapeutics's CEO is Mr. Daniel Barber.
Is Aquestive Therapeutics publicy listed? Yes, Aquestive Therapeutics is a public company listed on NAS.
What is the stock symbol of Aquestive Therapeutics? Aquestive Therapeutics trades under AQST ticker.
When did Aquestive Therapeutics go public? Aquestive Therapeutics went public in 2018.
Who are competitors of Aquestive Therapeutics? Similar companies to Aquestive Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Aquestive Therapeutics? Aquestive Therapeutics's current market cap is $249M
What is the current revenue of Aquestive Therapeutics? Aquestive Therapeutics's last 12-month revenue is $55.3M.
What is the current EBITDA of Aquestive Therapeutics? Aquestive Therapeutics's last 12-month EBITDA is -$30.7M.
What is the current EV/Revenue multiple of Aquestive Therapeutics? Current revenue multiple of Aquestive Therapeutics is 3.9x.
What is the current EV/EBITDA multiple of Aquestive Therapeutics? Current EBITDA multiple of Aquestive Therapeutics is -7.0x.
What is the current revenue growth of Aquestive Therapeutics? Aquestive Therapeutics revenue growth between 2023 and 2024 was 14%.
Is Aquestive Therapeutics profitable? Yes, Aquestive Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.